Please login to the form below

Not currently logged in
Email:
Password:

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

Ipsen Dr Claude BertrandIpsen's executive vice president of research and development and chief scientific officer Dr Claude Bertrand has stepped down from his post.

He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent successor.

Dr Bertrand joined the French pharmaceutical firm in 2009, having moved from AstraZeneca where he most recently served as global vice president for launched and established brands.

Prior to this, Dr Bertrand held director-level and senior research positions at Novartis, Pfizer and Roche.

David Meek, chief executive officer of Ipsen, said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years.

“We wish him well as he moves on to pursue a new opportunity.”

He added: “We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”

12th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics